VIRAL VECTORS, VACCINES AND EXOSOMES

CELL LINES FOR

Specifically designed for the purpose of RCA-free Adenoviral vector production CEVEC’s proprietary CAP® Technology based on human suspension cells is the ideal and highly scalable production platform for the manufacturing of Adenoviral vectors from research grade and smaller amounts up to industrial scale.

MOVE TO AN
RCA-FREE ADENOVIRUS PRODUCTION PROCESS
RIGHT FROM THE START

HUMAN CELL LINE

Non-tumor cell line derived from human amniocytes

FULLY DOCUMENTED

Complete documentation of cell line development and full certification of materials

HIGH SCALABILITY

Suspension cell line growing at high cell densities for high yields

FULLY TESTED

GMP MCB tested according to ICH guidelines and WHO recommendations. Biologics Master File on file at U.S. FDA

In addition to Adenoviral vectors, CAP® cells have also proven to be an efficient host cell line for the production of viral vaccines, Lentiviral vectors, Oncolytic viruses, and Exosomes.

HOW TO ACCESS OUR TECHNOLOGY AND SERVICES

First adeno viral vector production studies are typically performed as small scale transient transfection experiment, usually at our customer’s site or their chosen CMO.

Transfer of cells

CEVEC provides the CAP® cells as well as all required cultivation protocols, methods and processes.

Technology Transfer

A full in person technology transfer is done at the production site.

GMP production

CEVEC provides access to GMP compliant MCB and upstream & downstream production services for CAP® derived viral vector applications.

Licensing

Subject to the execution of an individualized R&D, clinical or commercial license, CEVEC assists to select the appropriate CDMO partner enabling a smooth technology transfer.

Regulatory Support

For dossier filings with regulatory agencies, CEVEC provides CAP® related support.

© CEVEC Pharmaceuticals GmbH 2020